152 related articles for article (PubMed ID: 22393192)
1. Predictive biomarkers in advance of a companion drug: ahead of their time?
Kelley RK; Atreya C; Venook AP; Febbo PG
J Natl Compr Canc Netw; 2012 Mar; 10(3):303-9. PubMed ID: 22393192
[TBL] [Abstract][Full Text] [Related]
2. The US Food and Drug Administration perspective on cancer biomarker development.
Gutman S; Kessler LG
Nat Rev Cancer; 2006 Jul; 6(7):565-71. PubMed ID: 16794639
[TBL] [Abstract][Full Text] [Related]
3. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
4. Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.
Dobbin KK; Cesano A; Alvarez J; Hawtin R; Janetzki S; Kirsch I; Masucci GV; Robbins PB; Selvan SR; Streicher HZ; Zhang J; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():77. PubMed ID: 27891226
[TBL] [Abstract][Full Text] [Related]
5. FDA and CLIA oversight of advanced diagnostics and biomarker tests.
Terry SF
Genet Test Mol Biomarkers; 2010 Jun; 14(3):285-7. PubMed ID: 20578940
[No Abstract] [Full Text] [Related]
6. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
Philip R; Carrington L; Chan M
Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
[TBL] [Abstract][Full Text] [Related]
7. Predictive biomarkers and clinical evidence.
Jørgensen JT
Basic Clin Pharmacol Toxicol; 2021 May; 128(5):642-648. PubMed ID: 33665955
[TBL] [Abstract][Full Text] [Related]
8. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
9. How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.
Seo MK; Cairns J
BMC Cancer; 2021 Sep; 21(1):980. PubMed ID: 34470603
[TBL] [Abstract][Full Text] [Related]
10. Companion diagnostic testing for targeted cancer therapies: an overview.
Fan YS
Genet Test Mol Biomarkers; 2013 Jul; 17(7):515-23. PubMed ID: 23574530
[TBL] [Abstract][Full Text] [Related]
11. Translating Immuno-oncology Biomarkers to Diagnostic Tests: A Regulatory Perspective.
Li Y; Veeraraghavan J; Philip R
Methods Mol Biol; 2020; 2055():701-716. PubMed ID: 31502175
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic kits in parasitology: which controls?].
Rossi P
Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
[TBL] [Abstract][Full Text] [Related]
13. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.
Tahara H; Sato M; Thurin M; Wang E; Butterfield LH; Disis ML; Fox BA; Lee PP; Khleif SN; Wigginton JM; Ambs S; Akutsu Y; Chaussabel D; Doki Y; Eremin O; Fridman WH; Hirohashi Y; Imai K; Jacobson J; Jinushi M; Kanamoto A; Kashani-Sabet M; Kato K; Kawakami Y; Kirkwood JM; Kleen TO; Lehmann PV; Liotta L; Lotze MT; Maio M; Malyguine A; Masucci G; Matsubara H; Mayrand-Chung S; Nakamura K; Nishikawa H; Palucka AK; Petricoin EF; Pos Z; Ribas A; Rivoltini L; Sato N; Shiku H; Slingluff CL; Streicher H; Stroncek DF; Takeuchi H; Toyota M; Wada H; Wu X; Wulfkuhle J; Yaguchi T; Zeskind B; Zhao Y; Zocca MB; Marincola FM
J Transl Med; 2009 Jun; 7():45. PubMed ID: 19534815
[TBL] [Abstract][Full Text] [Related]
14. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
Davis AA; Patel VG
J Immunother Cancer; 2019 Oct; 7(1):278. PubMed ID: 31655605
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers and biomarker validation: a pathologist's guide to getting it right.
Paver EC; Morey AL
Pathology; 2024 Mar; 56(2):147-157. PubMed ID: 38195376
[TBL] [Abstract][Full Text] [Related]
16. Approval of novel biomarkers: FDA's perspective and major requests.
Scherf U; Becker R; Chan M; Hojvat S
Scand J Clin Lab Invest Suppl; 2010; 242():96-102. PubMed ID: 20515286
[TBL] [Abstract][Full Text] [Related]
17. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.
Febbo PG; Ladanyi M; Aldape KD; De Marzo AM; Hammond ME; Hayes DF; Iafrate AJ; Kelley RK; Marcucci G; Ogino S; Pao W; Sgroi DC; Birkeland ML
J Natl Compr Canc Netw; 2011 Nov; 9 Suppl 5():S1-32; quiz S33. PubMed ID: 22138009
[TBL] [Abstract][Full Text] [Related]
18. Search for shortcuts on the critical path to market: US FDA perspectives from the diagnostic side.
Gutman S; Hackett J
Pharmacogenomics; 2006 Dec; 7(8):1223-7. PubMed ID: 17184209
[TBL] [Abstract][Full Text] [Related]
19. An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies.
Beaver JA; Tzou A; Blumenthal GM; McKee AE; Kim G; Pazdur R; Philip R
Clin Cancer Res; 2017 Mar; 23(6):1368-1372. PubMed ID: 27993967
[TBL] [Abstract][Full Text] [Related]
20. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.
Fridlyand J; Simon RM; Walrath JC; Roach N; Buller R; Schenkein DP; Flaherty KT; Allen JD; Sigal EV; Scher HI
Nat Rev Drug Discov; 2013 Oct; 12(10):743-55. PubMed ID: 24008432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
